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A B S T R A C T
Outer membrane vesicles (OMVs) are naturally non-replicating, highly immunogenic spherical nanoparticles
derived from Gram-negative bacteria. OMVs from pathogenic bacteria have been successfully used as vaccines
against bacterial meningitis and sepsis among others and the composition of the vesicles can easily be
engineered. OMVs can be used as a vaccine platform by engineering heterologous antigens to the vesicles. The
major advantages of adding heterologous proteins to the OMV are that the antigens retain their native
conformation, the ability of targeting specific immune responses, and a single production process suffices for
many vaccines. Several promising vaccine platform concepts have been engineered based on decorating OMVs
with heterologous antigens. This review discusses these vaccine concepts and reviews design considerations as
the antigen location, the adjuvant function, physiochemical properties, and the immune response.
1. Vaccine platforms
Many vaccines are developed based on Pasteur's principle: “isolate,
inactivate and inject” or by the selection of attenuated strains (Rappuoli
2004). Although many very effective vaccines have been developed by
these methods, they have often led to adverse effects. Nowadays,
vaccines must combine the lowest possible adverse effects with a high
efficacy. Vaccine platforms can standardize the provoked immune
response with high safety and low adverse effects, while the design
allows for easy switching of displayed antigens leading to high efficacy.
Protection against different diseases can be addressed by presenting
different antigens.
The development of a highly safe and effective vaccine requires a lot
of resources and time. At the same time the upcoming post-antibiotic
era may require the development of more vaccines that also need to be
developed in a short period (WHO 2014). The development trajectory
can be shortened by vaccine platforms (Kushnir et al. 2012), since these
platforms provide a blueprint for development of many different
vaccines instead of a specific development trajectory for each separate
vaccine with all its uncertainties. The safety of a vaccine platform can
be established by thorough development of the platform itself. Once the
safety and efficacy of a platform has been established, development
time can be reduced for new vaccines, since less testing will be required
and unexpected failures will occur less. This advantage of vaccine
platforms will reduce significantly the time to market, which is
notoriously long for new vaccines.
A vaccine platform should provoke a strong specific immune
response. This response is triggered by conformationally correct antigen
presentation, PAMPs (see glossary) to activate antigen presenting cells,
and a nanosized particulate nature. Furthermore, it should be possible
to easily add antigens onto the vaccine platform. Platform nanovaccines
can be based on many components, for example VLPs, ISCOMs,
polymeric nanoparticles, inorganic nanoparticles, liposomes, and emul-
sions. A component that is often overlooked are OMVs (Zhao et al.
2014). While many nanoparticles are capable of transferring hetero-
logous antigens to antigen presenting cells, the ability to properly
stimulate the immune system is often not natively present (Singh et al.
2007). OMVs, however, combine antigen presentation with proper
adjuvant properties, making them highly suitable as a vaccine platform.
OMVs are non-replicative vesicles that are naturally produced by
Gram-negative bacteria and contain excellent intrinsic immunostimu-
latory properties based on their particulate nature and composition
(Ellis and Kuehn 2010). The vesicles consist of phospholipids, LPS,
outer membrane proteins and entrapped periplasmic components (Kulp
and Kuehn 2010). OMVs are ascribed many biological functions such as
cell to cell communication, surface modifications and the expulsion of
components (Kulp and Kuehn 2010). Overall, OMVs have been shown
to be highly stable even upon elevated temperatures and several
chemical treatments (Arigita et al. 2004). This review addresses the
latest state of research with respect to the development of an OMV
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based vaccine platform. First we discuss the location of the antigen,
which is either inside the OMV or displayed on the OMV surface.
Location is important for the provoked type of immune response. Two
approaches of location specific antigen addition are discussed, namely
the endogenous addition based on antigen production by the bacterium
itself and the exogenous methods that introduce the antigen in a
separate process step. The bioengineering of the provoked immune
response and the endotoxicity is discussed. Additionally, we discuss the
bioengineering of the physiochemical properties of the OMV and the
potential of outer membrane vesicles as vaccine platforms. Lastly we
propose a uniform naming of different vesicles based on the origin of
the OMVs.
2. Designing the OMV: antigen location
Heterologous antigens on OMVs can be presented with or without
surface exposure, attached to the vesicle or non-attached and directly
produced by the bacterium or combined in a later production stage.
Various possibilities of antigen locations and their production method
are schematically shown in Fig. 1. At this moment it is unclear what the
most preferred setup for an OMV based vaccine platform is. This section
describes the impact of the heterologous antigen location, the endo-
genous loading of antigens to the vesicle lumen and the vesicle surface,
and the exogenous loading of antigens to the vesicle lumen and the
vesicle surface.
Surface exposed antigens are accessible for antigen-specific B cell
binding, while the inside of the vesicle is shielded from these cells.
Luminal antigens may be skewed towards cytotoxic T-cell responses
(Galen and Curtiss, 2014), hence the desired immune response deter-
mines the design of the OMV. Many groups have expressed antigens in
the lumen of OMVs to develop OMV vaccines (Table 1) (Bartolini et al.
2013; Fantappie et al. 2014; Kesty and Kuehn 2004; Kim et al. 2009;
Muralinath et al. 2011; Schild et al. 2009). Surprisingly, these studies
also find antibody-mediated immune responses against the luminal
heterologous antigen. Muralinath et al. studied the luminal expression
of Pneumococcal PspA in Salmonella enterica serovar Typhimurium
OMVs (Muralinath et al. 2011). These vesicles triggered minor antibody
responses against OMVs and PspA in immunized mice and provided
protection in a challenge experiment. OMVs without PspA or purified
PspA alone did neither evoke an antibody response nor provide
protection. Schild et al. showed minor specific antibody responses
against periplasmic alkaline phosphatase (PhoA) from Escherichia coli
expressed in Vibrio cholerae OMVs (Schild et al. 2009). In addition to the
minor antibody titers found in the previous two studies, it was shown
by Fantappie et al. that also high functional antibody titers can be
obtained by expressing heterologous antigens in their native conforma-
tion in the lumen of E. coli OMVs (Fantappie et al. 2014). This
systematic study characterized the vesicles by showing incorporation
of the antigens and antigen localization. Because of the findings in a
previous study that the Chlamydial HtrA protein expressed in OMVs
was partially surface exposed, the authors checked the antigen localiza-
tion (Box 1) by proteinase K treatment (Bartolini et al. 2013). After all,
contamination with surface exposed antigen could be a cause for the
observed response. The heterologous antigens in OMVs were found not
to be surface exposed. Further analysis of these proteins showed their
native conformation in the vesicle lumen that remarkably appears to be
sufficient to trigger antibody mediated responses.
Antigens can be presented on the surface of the OMV with exposure
to the exterior side of the vesicle. We recently studied the expression of
the Borrelial surface-exposed lipoprotein OspA in Neisseria meningitidis
OMVs (Salverda et al. 2016). Expression of the protein in meningococci
did not result in surface exposure on OMVs. To obtain surface exposure,
OspA was fused to a Neisserial lipoprotein. The immunogenicity of this
surface exposed fusion construct was compared to that of a luminal
expressed OspA in mice. Results showed that only the surface-exposed
OspA was able to elicit an OspA-specific antibody response. In a study
on Salmonella OMVs by Muralinath et al., higher immune responses
against outer membrane proteins and LPS were found than against the
heterologous expressed antigen present in the vesicle lumen
(Muralinath et al. 2011).
It remains unclear whether antigens in the lumen of OMVs provide
sufficient antibody responses. The observed antibody responses of some
studies may be biased by extracellular antigen or surface attached
antigen. On the contrary the lack of an antigen specific antibody
response against non-surface exposed OspA may not be predictive for
other antigens (Salverda et al. 2016). Antibody responses have been
observed for all surface exposed antigens, while for luminal antigens
the provoked responses remain ambiguous. Altogether more research is
required on the exact effect of the antigen location on efficacy of an
OMV vaccine platform.
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Fig. 1. Methods of antigen decoration on OMVs. Top row shows surface exposed antigens on the vesicles, bottom row shows the antigens as luminal cargo of OMVs. Antigens can be
produced by the OMV production bacterium (left), while antigen addition to purified vesicles can be divided in mixing, conjugation and encapsulation (middle and right).
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2.1. Endogenous loading of surface exposed antigens
Recombinant expression of proteins in bacteria is a large and ever-
growing field (Baneyx and Mujacic 2004; Rosano and Ceccarelli 2014).
Several approaches have been described to express proteins on the
outer membrane of bacteria (van Bloois et al. 2011). However, many of
these approaches have a low yield or are only suited for small proteins
or parts thereof. One method relies on antigenic proteins that are
normally exported beyond the cell surface by proteolytic processing.
These antigens can be retained by preventing the proteolysis (Georgiou
and Segatori 2005). Another method relies on targeting the protein to
the outer membrane and thus to the OMVs (Kesty and Kuehn 2004).
One of the first concepts of outer membrane targeting for surface
exposed antigen expression was based on autotransporters. Autotran-
sporters are transported as unfolded protein over the inner membrane
via the Sec pathway. Next, the autotransporter is transported over the
outer membrane by a so far unknown mechanism that most likely
requires direct involvement of the BamA protein (Sauri et al. 2009). The
rightly folded autotransporter anchors to the outer membrane via a C-
terminal β domain. Fusion to the autotransporter hemoglobin protease
(Hbp) of E. coli was used to express recombinant proteins in an
attenuated strain of Salmonella typhimurium (Jong et al. 2014). The
authors engineered Hbp to facilitate the surface expression of Myco-
bacterium tuberculosis proteins and epitopes of the major outer mem-
brane protein MOMP from Chlamydia thrachomatis (Daleke-
Schermerhorn et al. 2014). This method of antigen display is highly
efficient, however it seems limited to smaller protein fragments (Luirink
and Jong 2016).
To express larger proteins on the surface of the outer membrane,
Kim et al. fused several heterologous protein including GFP with a five-
residue glycine linker to the C-terminus of the pore-forming cytotoxin
ClyA (Kim et al. 2008). These fusion constructs were efficiently
transported across the inner membrane to the outer membrane of E.
coli. Recently it was shown by their group that surface expressed M2e
antigens on E. coli OMVs provided protection against influenza A
infection in a mice study (Rappazzo et al. 2016). Besides single M2e-
ClyA fusion constructs, the authors also successfully constructed a
nearly 50 kDa multimeric variant containing the serine analogs of
human, swine and two avian M2e variants. Apart from incorporation of
a single protein on the OMV it was shown in a different study that a
three-enzyme cascade could also be successfully engineered on E. coli
OMV (Park et al. 2014). The enzyme scaffold was expressed in the
bacterium and anchored to the outer membrane by the truncated ice
nucleation protein anchor (Shimazu et al. 2003). The enzymes were
produced separately from the OMV, which would allow the expression
of different enzymes on the OMV by simple replacement of these
enzymes for different proteins. The enzymes were attached to the
protein anchor by using three cohesion-dockerin pairs. Cohesin do-
mains interact with dockerin domains of enzymes to form multiprotein
complexes (Carvalho et al. 2003). To decorate the OMV with a three-
enzyme cascade, the authors used the unique interaction between each
of the three cohesion-dockerin pairs for the sequential attachment of
the enzyme complex. The OMVs with the enzyme scaffold had a 23-fold
higher conversion rate when compared to the individual enzymes free
in solution (Park et al. 2014). Although this example is not related to
vaccines it shows the potential of attaching proteins to the outside of
the OMV.
Surface exposed expression of heterologous lipoproteins has been
achieved by fusion of the heterologous lipoprotein to a membrane
anchoring second lipoprotein. In this way, the heterologous lipoprotein
signaling is not required to match the hosts signaling to achieve surface
exposure. The borrelial lipoprotein OspA was fused via a tether to the
N-terminal part of factor H binding protein that acts as a membrane
anchor (Salverda et al. 2016). The extracted OMV (eOMV) contained
surface exposed OspA. With this approach it was possible to purify
OMVs with surface exposed heterologous lipoprotein antigens.
2.2. Endogenous loading of antigens to the OMV lumen
Differences in protein composition of OMVs and the outer mem-
brane have been described (Haurat et al. 2011; Lappann et al. 2013;
Veith et al. 2014). This difference hints towards a regulated protein
sorting to OMVs or a regulated OMV release but the mechanism of
protein enrichment remains unclear. Accumulation of misfolded and
aggregated proteins in the periplasm is suggested as one of the possible
mechanisms of vesicle release (Kulp and Kuehn 2010). An increase in
OMV formation was found in strains lacking the chaperone DegP,
resulting in enrichment of misfolded DegP substrates in OMVs
(Schwechheimer and Kuehn 2013). McBroom and Kuehn showed that
it was possible to selectively enrich a protein in the OMV lumen by
adding a misfolded outer membrane protein sequence to the periplas-
mic cytochrome b562 (McBroom and Kuehn 2007). A 12-fold enrich-
ment of cytochrome b562 in OMVs was observed based on SDS-PAGE
analysis. Although this method provides valuable insights in the
method of protein sorting in OMVs, it may not be beneficial for the
folding of the antigen. Thus this method might not be preferred for the
addition of antigens that require proper folding in the lumen of OMVs.
Antigens have been bioengineered to be targeted to the lumen of
OMVs. Kesty and Kuehn fused GFP to the twin-arginine (Tat) signal
sequence to produce E. coli OMVs with GFP in their lumen. This Tat
pathway transfers folded proteins over the cytoplasmic membrane. To
transfer unfolded proteins over the cytoplasmic membrane the Sec
pathway could be used. However, GFP and some other proteins are
unable to fold correctly in the periplasm. The OMVs, containing GFP in
their lumen, showed to shield GFP from proteinases, which indicates
the stability of proteins inside the vesicles (Kesty and Kuehn 2004).
Another method for luminal protein expression in E. coli OMVs is based
on the fusion of proteins to the periplasmic side of the abundant outer
membrane protein OmpA (Kim et al. 2009). A FLAG-tag was attached to
the truncated C-terminus of the OmpA protein, which is located at the
periplasmic side of the outer membrane (Kim et al. 2009). OmpA
truncations or deletions are known to result in a blebbing phenotype.
Box 1
Analyzing the surface exposure of antigens on OMVs.
Analysis of the surface exposed protein expression is important, but challenging. Expression levels of the antigen can be assessed by
immunostaining. The heterologous antigen expressed on the bacteria and on the OMV can be stained by a labeled antibody and detected by
fluorescent microscopy (Salverda et al. 2016). Alternative options for the detection of immunostained bacteria or vesicles can be flow
cytometry (Rioux et al. 2001), ELISA or nanoparticle tracking analysis. Besides immunostaining, proteins associated to the outside of the
outer membrane can be determined by proteinase K digestion of surface exposed proteins followed by SDS-PAGE analysis. Western Blotting
can be used to test the proteinase K susceptibility of a specific antigen. This method has been used since the early 1980s for the detection of
surface exposed proteins (Freudl et al. 1986). The protein profile of proteinase K treated vesicles can be compared to the protein profile of
non-treated OMVs to detect proteinase K susceptibility of certain proteins. As a control, SDS can be added to the treatment to check the
digestion of previously shielded proteins.
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This approach combines stimulation of OMV production by the host
with a site for antigen addition. This method was successfully used to
express fusions of OmpA to several different antigens against Group A
Streptococcus, Group B Streptococcus and Chlamydia (Bartolini et al.
2013; Fantappie et al. 2014).
Another study has directed the pneumococcal protein PspA to the
lumen of Salmonella typhimurium OMVs by fusion of PspA to the N-
terminal β-lactamase signal sequence (Muralinath et al. 2011). This
signal sequence allows the transport of β-lactamase to the periplasm by
the type II secretion system, which yields OMVs with PspA in their
lumen.
Taken together, heterologous antigens can be expressed in the
lumen of OMVs by fusion of the antigen to secretion signals or
periplasmic proteins. These fusion based methods are relatively
straightforward and have been successfully used to express full size
antigens in a conformational correct manner and antibody have been
found against these antigens. While it is unclear how the antigens are
processed to eventually elicit antibody mediated immune responses,
heterologous expression of antigens in the lumen of OMVs may be a
feasible approach for an OMV vaccine platform.
2.3. Exogenous loading of surface exposed antigens
Antigens can be added afterwards by introducing affinity to the
antigen on the OMV. This method of exogenous loading was used by
adding a SpyTag to OmpA (Alves et al. 2015). The SpyTag peptide is
designed to form a covalent bond with the SpyCatcher protein to ease
conjugation of proteins (Zakeri et al. 2012). The SpyTag-OmpA fusion
was expressed on OMVs and can be coupled to SpyCatcher fused to any
protein. By this method, OMVs can be produced in mass production
followed by adding antigens on the OMV. Similarly, this SpyTag based
approach has been used to decorate VLPs with antigens as vaccine
platform (Brune et al. 2016).
2.4. Exogenous loading of antigens to the OMV lumen
Loading of antigens to the vesicle lumen, after the vesicles and
antigens have separately been produced in bulk, can be an attractive
approach. The concentration of the active components may be better
controllable when compared to endogenous loading. To load antigens
in their native conformation to the OMV lumen in vitro, the vesicle
should be opened and closed again without permanent damage. The
exogenous loading of proteins to the vesicle lumen has not been
described although several methods of loading smaller molecules into
extracellular vesicles (EVs) are explored. EVs can be loaded by simple
incubation (passive loading) or by active treatment of the EVs (active
loading). Methods of loading EVs by electroporation, saponin-treat-
ment, extrusion or dialysis are well described for EVs and even
compared in a side by side study (Fuhrmann et al. 2015). In this study
different porphyrins were loaded in endothelial, stem cell, and cancer
derived EVs. Active encapsulation techniques and especially saponin-
treatment showed higher porphyrin loading than passive techniques.
Active encapsulation by electroporation has been described to load
small-molecule drugs and siRNA in to EVs (reviewed in Lamichhane
et al. 2015). Active encapsulation of siRNA in to E. coli OMVs by
electroporation was applied by Gujrati et al. (2014). This siRNA targets
kinesin spindle protein, which is upregulated in tumor and rapidly
growing cells. The siRNA was electroporated to the lumen of the OMV
resulting in intact siRNA-loaded vesicles. The loaded vesicle was
targeted to HER2+ tumor cells by a HER2 antibody fused to ClyA.
The authors were successful in reducing tumor growth in mice by
treatment with these OMVs. For the loading of vesicles derived from the
fungus Neurospora crassa, a single freeze-thaw method has been shown
to be very effective (Mayer et al. 1995). Loading efficiencies of over
80% were reported and the authors claim the method is suitable for any
protein. Interestingly, this method has to our knowledge not been tested
for bacterial OMVs.
2.5. Mixing OMVs
It is currently unknown whether antigens require attachment to the
vesicles. It has been shown that for Adjuvant System 03, a marketed oil
in water adjuvant, it is sufficient to inject the antigen at the same
location as the adjuvant to obtain an adjuvating effect (Morel et al.
2011). In this case, simple mixing of the adjuvant and antigen is
sufficient. The mixing of the weak antigen GFP with E. coli OMVs
showed however, that immunized mice did not elicit anti-GFP IgG
responses (Chen et al. 2010). Attachment of GFP to the OMVs did show
enhanced responses, comparable to GFP absorbed to the commercial
standard adjuvant alum. Alternatively, antigens can be conjugated to
the OMV if attachment is desired. This has been successfully accom-
plished for Brucella LPS that was conjugated to N. meningitidis OMVs
(Siadat et al. 2015). Along the same line capsular polysaccharides from
serogroup C meningococci were conjugated to a N. meningitidis ser-
ogroup B OMV (Fukasawa et al. 2006). Using conjugation, mixing,
heterologous expression, or a combination thereof, also multivalent
vaccines can be designed using OMVs as a main component. A
combination of mixing and recombinant antigen expression has been
applied for the eOMV based N. meningitidis serogroup B concept
vaccines Hexamen and Nonamen (Claassen et al. 1996; Kaaijk et al.
2013). Mixing dOMVs from two strains has been applied to produce a
combined N. meningitidis serogroup A and W concept vaccine (Tunheim
et al. 2013). Mixing OMVs has been applied by a recently proposed
sOMV based Shigellosis concept vaccine (Mitra et al. 2013). The
authors of this latter study produced sOMV from 6 serogroups of
Shigella that were mixed to form a hexavalent vaccine. This composi-
tion was named MOMV (not to be mistaken with modified OMVs or the
previous naming of mitochondrial EVs, see Box 2 for naming of
different types of OMVs) because of the multi-serotype OMV composi-
tion (Mitra et al. 2013). Roier et al. created OMV mixtures of nontype-
able H. influenzae strains to obtain a broad covering immunization
mixture (Roier et al. 2012). The OMV mixture showed a broadly
covering protective immune response, although it should be noted that
OMVs derived from a single strain also showed cross-protection against
other nontypeable H. influenzae strains. Mixing of OMVs from enter-
otoxigenic E. coli and V. cholerae was described by Leitner and
coworkers (Leitner et al. 2015). The authors showed an improved
protection for the mixed OMVs when compared to the provoked
immune response from the individual OMVs alone. Mixing of OMVs
can thus be a simple yet very effective method of improving protection.
3. Designing the OMV: bioengineering the immune response
The interaction of the OMV with the immune system can be
considerably tuned. Outer membrane vesicles can be directly used as
a vaccine, since the vesicles are non-replicating and contain antigens as
well as PAMPs in a particle configuration. Furthermore, OMVs can
induce both humoral and cellular immune responses (Ellis and Kuehn
2010). Recently it was shown by Rosenthal et al. that E. coli OMVs can
trigger a Th1-biased immune response (Rosenthal et al. 2014). The
authors were able to induce both protective humoral and Th1-biased
cellular immune responses against the heterologous antigen by using
the probiotic E. coli Nissle 1917 bacteria as OMV production host. This
probiotic bacterium itself is highly immunosuppressive, and thus not an
obvious vaccine candidate, nevertheless its OMVs lack this capacity
(Kim et al. 2013). In contrast to the OMVs from E. coli K12, the
probiotic derived OMVs elicit Th1 cellular immune responses, however
these responses were not necessarily directed against the heterologous
expressed antigens (Rosenthal et al. 2014). To improve the immune
response against an antigen of interest, the antigen amount per OMV
can be increased or multiple antigens can be included. Zhang and co-
workers improved the immunogenicity of a trivalent N. meningitidis
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vaccine by genetic engineering a second fHbp protein in the porB gene,
which increased fHbp yields in the OMV and increased antibody
responses against fHbp (Zhang et al. 2016).
OMVs can be engineered such that the vesicles contain proteins
altered in their interaction with human receptors. Opacity (Opa)
proteins of Neisseria sp. are known to interact with human CEACAM
receptors (Billker et al. 2000). This interaction causes a reduced Opa-
specific immune response, however the immune response against the
other OMV antigens was not significantly affected (Zariri et al. 2013).
Another hypothesis is that binding of OMV proteins by human
complement inhibitors could interfere with the development of the
immune response. A reduction in antibody responses was shown due to
binding of the antigen with a human protein (Costa et al. 2014). Human
factor H could be bound by Neisserial fHbp, NspA and Porin B2.
Especially the interaction with fHbp is studied widely due to the recent
licensing of two fHbp based N. meningitidis serogroup B vaccines
(Marshall et al. 2013; Serruto et al. 2012). It was shown that partial
inhibition of fH binding did not enhance the immunity in a mouse
model (Daniels-Treffandier et al. 2016). Human Factor H transgenic
mice were immunized with a low fH binding mutant of fHbp and
showed to elicit higher serum bactericidal antibody responses than
when immunized with fHbp capable of binding fH (Rossi et al. 2013).
Furthermore, immunizations with a low fH binding recombinant fHbp
mutant in an infant rhesus macaques model showed antibody responses
directed to the region of fHbp that binds human factor H (Granoff et al.
2016). Antibody responses against these host protein binding antigens
can be improved by low-binding mutants, although these show no
alteration in the antibody responses against other proteins present on
the OMV.
OMVs contain by nature many immunogenic components that could
cause a reaction against the OMV backbone. Currently it is unknown
whether this reaction causes undesired effects. The possibility of this
effect affects the choice of backbones (Table 1). The use of E. coli as
backbone has the advantage of being extensively studied (Bartolini
et al. 2012; Basto et al. 2012; Chen et al. 2016; Fantappie et al. 2014;
Huang et al. 2016; Kesty and Kuehn 2004; Kim et al. 2008; Kim et al.
2009; Price et al. 2016; Pritsch et al., 2016; Rappazzo et al. 2016;
Schroeder and Aebischer 2009), however the immune response directed
against E. coli could negatively influence commensal populations. This
negative effect could be prevented by the use of a pathogenic bacterium
as backbone. Pathogenic backbones as N. meningitidis, S. typhimurium
and V. cholerae have been described (Daleke-Schermerhorn et al. 2014;
Salverda et al. 2016; Schild et al. 2009), although it is unknown what
the effect is on the spread of the production pathogen itself. Another
aspect is the possible response against the backbone during the
repetitive use of the OMV platform against different diseases. Alter-
natively, a stealth backbone could be developed. Cross reactivity of the
backbone with closely related species was described for N. meningitidis
(Oliver et al. 2002; Sanchez et al. 2001) illustrating the possible broader
effect of immune responses against the OMV backbone. Currently it is
unknown to what extent minor cross-reactivity impacts a vaccine
platform or if a complete stealth OMV backbone is required.
4. Designing the OMV: bioengineering toxicity and adverse effects
As a very potent activator of the immune system, lipopolysaccharids
(LPS) can induce severe side effects and must be detoxified.
Detoxification by reducing the amount of LPS has been performed by
a detergent extraction process yielding dOMV (Zollinger et al. 1978). To
use native or spontaneous OMVs, most vaccine concepts are based on
genetically detoxified LPS, with potent activation of the innate immune
system by TLR4. The TLR4 activation can be altered by bioengineering
the LPS (Zariri et al., 2016b), since too potent TLR4 reactivity causes
endotoxicity (Fitzgerald et al. 2004). The endotoxin activity of LPS was
modified by msbA deletion in E. coli or lpxL1 deletion in N. meningitidis,
resulting in lipid A without the secondary acyl chain (Somerville et al.
1996; van der Ley et al. 2001). These modifications strongly alter the
endotoxicity by reducing the TLR4/MD-2 activation by the LPS. Further
bioengineering of N. meningitidis LPS showed that a broad range of
TLR4 activation can be obtained (Zariri et al., 2016b). Furthermore, a
broad range of differential cytokine inducing properties was observed
by the different bioengineered LPS species. LPS bioengineering to
reduce LPS reactivity has been applied on many different species
(Zariri and van der Ley 2015). Besides OMVs from bioengineered N.
meningitidis, vesicles with genetically detoxified LPS have also been
produced from E. coli and V. cholarae (Leitner et al. 2013; Leitner et al.
2015). Recently, E. coli OMVs containing only the lipid IVa of LPS
instead of the full LPS have been produced (Watkins et al. 2017). These
OMVs retained sufficient capabilities of eliciting immune responses
against the included heterologous antigens.
Box 2
Naming of OMVs.
With the production of extracted OMVs, many prefixes have been used to clarify the origin of the OMVs (van der Pol et al. 2015). The
naming of the different types of vesicles has been based on the method of extraction, for example, the detergent deoxycholate (DOC) has
been used to extract OMVs from bacteria to develop the first OMV-based vaccines (Sierra et al. 1991). This harsh extraction method was
used to decrease the toxic LPS in the vesicles and the produced vesicles were referred to as detergent OMVs (dOMVs). The use of prefixes in
OMV naming starts to become confusing due to the development of more and more methods of extracting vesicles and methods of increased
“spontaneous” release of vesicles in the culture supernatant. The term nOMV has been used for both natural OMVs and native OMVs, where
native OMVs were extracted by EDTA. It was shown that EDTA-extracted OMVs were similar to natural OMVs and hence the term nOMVs
or N-OMVs was used (van de Waterbeemd et al. 2010). To distinguish between spontaneous and extracted vesicles we favor to refer to
EDTA extracted vesicles as extracted OMV: eOMV. Moreover, spontaneously released OMV in vivo should be distinguished from OMV
released in vitro. The in vitro production of spontaneous released OMV during cultivations is known to be induced by many mutations or
stressors. The possible difference between these stress released vesicles and vesicles released spontaneously by the bacterium are more
difficult to observe and researchers should be careful when comparing differently produced OMV. We suggest to refer to in vitro produced
OMVs as supernatant OMVs: sOMVs. Overall it has become challenging to apply a uniform naming system of OMVs and thus it should be
cared for that the method of producing OMVs is accurately described. We propose to uniform the naming of OMVs as listed in Table 2.
Table 2
Overview of the proposed naming of OMVs.
Abbreviation Type of OMV
dOMV Detergent extracted OMVs from in vitro cultured bacteria
eOMV All non-detergent extracted OMV from in vitro cultured bacteria
mOMV Preferably not to be used due to its ambiguity (modified OMV,
multivalent OMV, mitochondrial OMV)
nOMV Preferably not to be used due to its ambiguity (native OMV or
natural OMV)
sOMV Spontaneous released OMV, typically obtained from the
supernatant of in vitro cultured bacteria
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Besides targeted attempts to alter the endotoxicity of the OMV, it is
important to take into account that the production method has severe
impact on the endotoxicity. It was shown that different OMVs (sOMV,
eOMV and dOMV, see Box 2) derived from the same strain have
differences in TLR4 and TLR2 activation (Zariri et al., 2016a). To
improve the OMV productivity of H. pylori, Tol-Pal knockouts were
constructed (Turner et al. 2015). However, the downside of the
increased vesicle production was the more potent induction of inflam-
mation of these OMVs, by significantly higher IL-8 levels, in host cells
than wildtype OMVs. This indicates once more the complexity involved
in the design of an OMV based vaccine.
Recently a novel type of vaccine platform based on OMVs was
described by two groups, based on heterologous expressed glycan
antigens instead of antigenic proteins (Chen et al. 2016; Feldman
et al. 2013; Price et al. 2016). These glyco-engineered OMVs (geOMVs)
designed by Price et al. are based on the similarity between the
polysaccharide translocation in the expression host and the vaccine
target (Price et al. 2016). The capsular polysaccharide of S. pneumoniae
was expressed in an E. coli strain lacking its own O-antigen yielding
attachment of the S. pneumoniae capsular polysaccharides to the E. coli
lipid A core. In another study, Chen et al. produced glycosylated OMVs
that provided protection against F. tularensis challenge in mice, by
expression of recombinant O-antigen polysaccharide on E. coli OMVs
(Chen et al. 2016). Furthermore, several lipid A modifications were
made resulting in lowered TLR4 activation similarly to the attempts of
detoxifying OMV associated LPS. The ease of adding heterologous
glycans on OMVs emphasizes the potential of an OMV based vaccine
platform for polysaccharide vaccines.
5. Designing the OMV: physiochemical properties
The size of OMVs is an overlooked part of OMV vaccine research
that is, however, very relevant since the size influences the uptake by
antigen presenting cells (APCs). Macrophages preferentially take up
larger particles (Fig. 2) where dendritic cells (DCs) take up particles in
the size range of OMVs and VLPs (Xiang et al. 2006). OMVs range in
size from 20 to 250 nm in diameter (Kulp and Kuehn 2010) and size is
assumed to be homogeneous and similar between different bacterial
species. However, minor differences are reported in the size distribu-
tions of sOMV, eOMV and dOMV from the same bacterium in similar
production processes (van de Waterbeemd et al. 2010). The size of
OMVs is important for the design of the production process (Klimentova
and Stulik 2015). For example, sterile filtration is only possible for
smaller sized OMVs. Moreover, a minimum size of OMVs is required for
adequate analysis of OMV quality. Conventional flow cytometry, for
example, is not suitable for the analysis of particles smaller than
300 nm (Steen 2004). Improvements on flow cytometry have been
made improving the detection limit (van der Vlist et al. 2012) and
methods focused on nanoparticles, such as Nanoparticle Tracking
Analysis (NTA) (Malloy and Carr 2006) and Tunable Resistive Pulse
Sensing (Vogel et al. 2011), have been developed. With these improved
methods a size limit of around 20 nm remains for appropriate detection
of nanoparticles.
The size and shape are important parameters in the field of synthetic
nanoparticles, and these physiochemical properties are highly tunable.
Recently Gao and co-workers made an interesting combination of
bacterial outer membrane vesicles and synthetic gold nanoparticles
(AuNPs) (Gao et al. 2015). OMVs were coated with mechanical force on
gold nanoparticles to produce 30 nm sized membrane-coated AuNPs.
Mice vaccinated subcutaneously with these nanoparticles showed rapid
activation of DCs in lymph nodes, while vaccination with 90 nm sized
membrane coated nanoparticles showed reduced accumulation of DCs.
The membrane coated AuNPs of 30 nm showed higher induction of
specific antibody responses, IFN-gamma production, and IL-17 produc-
tion when compared to OMVs alone. The IL-4 production was low for
all groups indicating a strong Th1- and Th17-biased cellular response.
Another study compared ovalbumin loaded styrene nanoparticles with
different size and shape, concluding that the smallest (193 nm)
spherical particles elicit the strongest Th1 and Th2 immune responses
(Kumar et al. 2015). This smaller spherical particle showed a Th1-
biased response while the larger (1530 nm) rod-shaped particle elicits a
Th2-biased immune response. Smaller nanoparticles (10–200 nm) are
able to drain freely to the lymph nodes, while larger nanoparticles
(500 nm - 2000 nm) require dendritic cells (Manolova et al. 2008). The
larger particles are thus unable to target cells residing in the lymph
nodes. Size of the vesicles is thus an important parameter in navigating
the immune response by the efficient uptake by antigen presenting cells
and efficient entry in to lymph nodes.
6. Concluding remarks and future perspectives
OMVs have been proven to be a flexible vaccine production plat-
Fig. 2. The size of vaccine concepts and the required size range for accessible production compared to the interaction with the immune system. The possibility of sterile filtration
simplifies the design of the production process, while the analysis of nanoparticle size and the number of nanoparticles is essential for quality control. The green box highlights the overall
preferred size window for vaccine production. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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form. Heterologous proteins and glycan antigens can be easily added to
the vesicle, the immune stimulating properties of the vesicle can be
engineered, and the toxicity can be reduced. Future research should
address the immune response against the platform backbone, the
heterogeneity of the vesicle product and the relatively underexplored
effects of luminal OMV components. Besides the use of OMVs as
prophylactic vaccines, vast possibilities of OMVs as therapeutic vac-
cines exist. With the approval of human use of several OMV based
meningococcal vaccines, the future of OMV vaccines is bright, paving
the way to designer and tailor made OMV vaccines. The use of OMV
based vaccine platforms will facilitate enhanced vaccine design and will
speed up the introduction of new much needed vaccines.
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Glossary
EVs: Extracellular vesicles are membrane structures derived from eukaryotic cells,
involved in intercellular communication. EVs are widely studied because of their
diagnostic and therapeutic potential.:
ISCOMs: Immune stimulating complexes, adjuvating spheres of approximately 40 nm
that can be combined with membrane antigens.:
M2e: the extracellular domain of the Matrix 2 protein of influenza A. M2e is evolutionary
conserved among influenza A viruses and widely studied as a possible universal
vaccine antigen.:
OspA: Outer surface protein A of Borrelia burgdorferi is one of the major surface proteins.
OspA has been the basis of LYMErix, a vaccine against Lyme's disease marketed until
2002.:
PAMPs: Pathogen associated molecular patterns that are recognized by pattern
recognition receptors to activate innate immune responses. Examples of PAMPs are
virus associated RNA, bacterial endotoxins, flagellin or LPS. The latter is specifically
recognized by the innate immune system via Toll-like receptor 4 (TLR4).:
SpyTag: A peptide derived from Streptococcus pyogenes (Spy) designed such that it can
form a covalent bond with SpyCatcher, a complementary domain. SpyTag/
SpyCatcher pairs can be used for bioconjugations.:
VLPs: Virus-like particles are virus structures without viral genetic material, which makes
them non-infectious. VLPs have been recently developed as new-generation of viral
vaccines.:
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